Biofrontera AG Profit Margin

The latest profit margin for B8F.DE is -13.78% as of June 2026. That compares with -42.35% in the prior-year period — up 67.4% year over year. That is below the Healthcare sector average of 9.71%. Investors often review this figure alongside Biofrontera AG's historical trend and sector peers before judging valuation or financial health.

Over the past year, B8F.DE's profit margin moved from -42.35% to -13.78% — a 67.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biofrontera AG's valuation or profitability profile.

Against Healthcare companies, B8F.DE currently prints -13.78% for profit margin, while the sector average sits near 9.71%. That is roughly 242.0% below the sector mean. Large gaps often invite a closer look at Biofrontera AG's growth, margins, and balance sheet.

Profit Margin shows how effectively Biofrontera AG converts resources into returns. At -13.78%, B8F.DE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -42.35% in the prior-year period — up 67.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting B8F.DE's profit margin (-13.78%), review year-over-year change from -42.35%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.